You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
億帆醫藥(002019.SZ):代謝類疾病和內分泌疾病是公司重點的發展領域
格隆匯 06-06 09:02

格隆匯6月6日丨億帆醫藥(002019.SZ)召開業績説明會,互動環節中,就“三代胰島素類似物上市策略。”

公司回覆稱,代謝類疾病和內分泌疾病是公司重點的發展領域。從研發策略上來看,三代胰島素類似藥在美國的價格進行了大幅下調,所以從申報策略上來看,美國市場我們還需要進一步進行評估;但是,歐洲和中國的申報策略目前沒有改變。針對內分泌和代謝類疾病其他創新藥產品,比如説雙激動劑等產品我們仍然計劃採用中、美、歐同步申報策略。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account